Search Results - "Haanen, J.B"

IOTECH in times of COVID-19 by Haanen, J.B.

Get full text

(Neo)adjuvant systemic therapy for melanoma by van Zeijl, M.C.T, van den Eertwegh, A.J, Haanen, J.B, Wouters, M.W.J.M

“…Abstract Surgery still is the cornerstone of treatment for patients with stage II and III melanoma, but despite great efforts to gain or preserve locoregional…”
Get full text

Vemurafenib for BRAF V600 mutated advanced melanoma: Results of treatment beyond progression by Scholtens, A, Geukes Foppen, M.H, Blank, C.U, van Thienen, J.V, van Tinteren, H, Haanen, J.B

“…Abstract Background Selective BRAF inhibition (BRAFi) by vemurafenib or dabrafenib has become approved standard treatment in BRAF V600 mutated advanced stage…”
Get full text

Vemurafenlb Improves Overall Survival Compared to Dacarbazlne In Advanced BRAFV600E-mutated Melanoma: Updated Survival Results From a Phase III Randomised, Open-label, Multlcentre Trial by McArthur, G, Hauschild, A, Robert, C, Haanen, J.B, Ascierto, P, Lee, R.J, Nolop, K, Nelson, B, Flaherty, K.T, Chapman, P.B

Get full text

485 Germline genetic association on efficacy of Immune-checkpoint inhibition in Metastatic Melanoma patients by Ouwerkerk, W., Chielie, S., Bekkenk, M., Van Doorn, R., CU blank, Haanen, J.B., Hospers, G.A., Kirchhoff, T., Luiten, R.

Get full text

Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma by Geukes Foppen, M.H., Brandsma, D., Blank, C.U., van Thienen, J.V., Haanen, J.B., Boogerd, W.

“…Historically leptomeningeal metastases (LM) from melanoma have a poor prognosis, with a median survival of only 2 months despite treatment. Targeted therapy…”
Get full text

Investigation of sex and gender differences in oncology gains momentum: ESMO announces the launch of a Gender Medicine Task Force by Özdemir, B.C., Oertelt-Prigione, S., Adjei, A.A., Borchmann, S., Haanen, J.B., Letsch, A., Mir, O., Quaas, A., Verhoeven, R.H.A., Wagner, A.D.

Get full text

Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry by Özkan, A., Kapiteijn, E., van den Bos, F., Aarts, M.J.B., van den Berkmortel, F.W.P.J., Blank, C.U., Bloem, M., Blokx, W.A.M., Boers-Sonderen, M.J., Bonenkamp, J.J., van den Eertwegh, A.J.M., de Groot, J.W.B., Haanen, J.B., Holtslag, C.E., Hospers, G.A.P., Piersma, D., van Rijn, R.S., Stevense-den Boer, A.M., Suijkerbuijk, K.P.M., van der Veldt, A.A.M., Vreugdenhil, G., Wouters, M.W.J.M., Portielje, J.E.A., de Glas, N.A.

“…Adjuvant anti-PD-1 therapy improves relapse free survival in stage III melanoma, but also leads to immune-related adverse events (irAEs). Older patients are of…”
Get full text

Phase 2 Study Comparing Pembrolizumab with Intermittent/short-term dual MAPK pathway inhibition plus Pembrolizumab(PEM) in patients harboring the BRAFV600 mutation (IMPemBra Trial) by Rozeman, E.A., Deken, M.A., Gadiot, J., Geukes Foppen, M.H., Pronk, L., Thienen, J.V., Haanen, J.B., Blank, C.U.

Get full text

Phase 2 Study Comparing Pembrolizumab with Intermittent/short-term dual MAPK pathway inhibition plus Pembrolizumab(PEM) in patients harboring the BRAFV600 mutation (IMPemBra Trial) by Rozeman, E.A., Deken, M.A., Gadiot, J., Geukes Foppen, M.H., Pronk, L., Thienen, J.V., Haanen, J.B., Blank, C.U.

Get full text

Neoadjuvant ipilimumab plus nivolumab in early stage colon cancer by Chalabi, M., Fanchi, L.F., Van den Berg, J.G., Beets, G.L., Lopez-Yurda, M., Aalbers, A.G., Grootscholten, C., Snaebjornsson, P., Maas, M., Mertz, M., Nuijten, E., Kuiper, M., Kok, M., Van Leerdam, M.E., Schumacher, T.N., Voest, E.E., Haanen, J.B.

Get full text

(Neo-)adjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage 3 melanoma – updated relapse free survival (RFS) data from the OpACIN trial and first biomarker analyses by Rozeman, E.A., Fanchi, L., van Akkooi, A.C.J., Kvistborg, P., Thienen, J.V., Stegenga, B., Lamon, B., Haanen, J.B., Schumacher, T.N.M., Blank, C.U.

Get full text

Combined radiofrequency ablation and ipilimumab in uveal melanoma: Results from the SECIRA-UM trial by Rozeman, E.A., Prevoo, W., Meier, M.A.J., Sikorska, K., van de Wiel, B.A., Broeks, A., van Tinteren, H., Kapiteijn, E., Thienen, J.V., Haanen, J.B., Blank, C.U.

Get full text

89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer by Kok, I.C., Hooiveld, J.S., van de Donk, P.P., Giesen, D., van der Veen, E.L., Lub-de Hooge, M.N., Brouwers, A.H., Hiltermann, T.J.N., van der Wekken, A.J., Hijmering-Kappelle, L.B.M., Timens, W., Elias, S.G., Hospers, G.A.P., Groen, H.J.M., Uyterlinde, W., van der Hiel, B., Haanen, J.B., de Groot, D.J.A., Jalving, M., de Vries, E.G.E.

“…Programmed cell death protein 1 (PD-1) antibody treatment is standard of care for melanoma and non-small-cell lung cancer (NSCLC). Accurately predicting which…”
Get full text

Phase 3 study of avelumab in combination with axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC) by Motzer, R.J., Choueiri, T., Larkin, J., Albiges, L., Haanen, J.B., Schmidinger, M., Atkins, M.B., Mariani, M., Shnaidman, M., Di Pietro, A., Rini, B.I.

Get full text

Nivolumab, ipilimumab and COX2-inhibition in early stage colon cancer by Chalabi, M., Van Leerdam, M., Aalbers, A., Van den Berg, J., Beets, G., Grootscholten, C., Snaebjornsson, P., Kuiper, M., Den Hartog, P., Weeber, F., Dijkstra, K., Kok, M., Cullen, D., Schumacher, T.N.M., Haanen, J.B., Voest, E.

Get full text

Antigen design enhances the immunogenicity of Semliki Forest virus-based therapeutic human papillomavirus vaccines by Ip, P P, Boerma, A, Walczak, M, Oosterhuis, K, Haanen, J B, Schumacher, T N, Nijman, H W, Daemen, T

“…Cellular immunity against cancer can be achieved with viral vector- and DNA-based immunizations. In preclinical studies, cancer vaccines are very potent, but…”
Get full text

A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM) by Weber, J., Long, G.V., Haanen, J.B., Arance, A., Dummer, R., Nathan, P., Ribas, A., Ascierto, P.A., Robert, C., Gasal, E., D’Amelio, A., Bettinger, S., Boran, A.D., Schadendorf, D.

Get full text

Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME) by Bex, A., Mulders, P., Jewett, M.A.S., Wagstaff, J., van Velthoven, R., Laguna Pes, P.M., Wood, L., van Melick, H.H.E., Soetekouw, P., Lattouf, J.B., Powles, T., Boleti, E., de Jong, I-J., Rottey, S., Tombal, B., Marreaud, S., Collette, L., Collette, S., Blank, C.U., Haanen, J.B.

Get full text

Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study by Chapman, P.B., Robert, C., Larkin, J., Haanen, J.B., Ribas, A., Hogg, D., Hamid, O., Ascierto, P.A., Testori, A., Lorigan, P.C., Dummer, R., Sosman, J.A., Flaherty, K.T., Chang, I., Coleman, S., Caro, I., Hauschild, A., McArthur, G.A.

“…The BRIM-3 trial showed improved progression-free survival (PFS) and overall survival (OS) for vemurafenib compared with dacarbazine in treatment-naive…”
Get full text